Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q3 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities.
The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements.
Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks.
The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
Pharmaceuticals & Biotechnology
Pharmaceuticals
200 Cr
Moderate Risk
0.0
36.7
—
0.3
22.49
9.20
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Nectar Lifescience Ltd (NECLIFE) is currently trading at 10.27 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities. The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements. Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks. The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
Over the past 52 weeks, Nectar Lifescience Ltd has traded between a low of ₹9.20 and a high of ₹22.49. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Nectar Lifescience Ltd has a market capitalization of approximately 200.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Nectar Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 200.09 Cr, Nectar Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Nectar Lifescience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Nectar Lifescience Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
582.00 | 208 Cr | 12.86 | 0.99 | 0.34 | 7.83 | 10.89 | 6.81 | ||
42.02 | 207 Cr | 18.94 | 1.69 | 0.00 | 8.93 | 13.60 | 3.25 | ||
154.05 | 201 Cr | — | 17.63 | 0.00 | -148.86 | -9.23 | -11.80 | ||
10.27 | 200 Cr | — | 0.34 | 0.00 | -9.85 | -8.75 | -47.12 | ||
273.75 | 198 Cr | — | 6.46 | 0.00 | 14.29 | 16.99 | 12.01 | ||
64.99 | 189 Cr | 7.69 | 1.54 | 0.00 | 20.04 | 19.30 | 16.59 | ||
51.35 | 188 Cr | — | 0.00 | 0.00 | 41.16 | -26.02 | -14.69 | ||
| Median: 7 Co. | — | 64.99 | 200 Cr | 12.86 | 1.54 | 0.00 | 8.93 | 10.89 | 3.25 |
Merger/Acquisition
Nectar Lifescience Ltd informs that it and Purchaser Capnest Health Care Pvt Ltd have mutually extended the expected completion date of the empty hard gelatin capsule slump sale to on or before 2026-12-31.
Merger/Acquisition
Nectar Lifescience Ltd informs exchanges that the slump sale of its Empty Hard Gelatin Capsule business to Capnest Health Care Pvt Ltd has been mutually extended to on or before 2026-12-31; other disclosures unchanged.
